.Nature Medication, Published online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) procedure of individuals with HER2+ state-of-the-art bosom cancer cells and energetic or even stable mind metastases presented steady intracranial activity as well as wide spread efficacy of T-DXd.